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688 LETTERS TO THE EDITOR
Toxicities of the antifolate, CB3717
Sir - In the recent article by Harding et al. (1988) the
toxicities of the antifolate, CB3717, are discussed in the
summary. It is stated that, in contrast to the results of our
own published work (Calvert et al., 1986), AST levels did
not diminish with repeated courses of treatment but the
administration of prednisone was effective in reducing them,
although no data are presented to support these claims.
In our own study we did not report on AST levels.
However we did find that the more hepatospecific enzyme,
ALT, diminished on repeated dosage, but only at the fourth
course of treatment. In the study recently presented 75
courses were given to 26 patients, so presumably very few
received 4 or more courses. In our own study ALT levels
also displayed a marked inter-patient variability. When this
was accounted for no effect of prednisolone administration
on the ALT levels could be detected in 23 patients, although
the associated malaise was reduced.
Yours etc.
Clinical Pharmacology,
The Institute of Cancer Research,
Royal Cancer Hospital,
Block E, 15 Cotswold Road,
Belmont, Sutton,
Surrey, SM2 5NG, UK.
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